Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016 > vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes

vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes

Read also

FDA Announces New Domestic Generic Drug Fast-Track Review Program
FDA Announces New Domestic Generic Drug Fast-Track Review Program
FDA announced a new pilot program designed to provide faster reviews for domestically tested and manufactured generic drugs.
Rocket Company
Rocket Company
Rocket ditches blood disorder gene therapy in ongoing pipeline pivot
AAVantgarde Announces FDA
AAVantgarde Announces FDA
AAVantgarde Announces FDA Orphan Drug Designation and UK CTA approval for AAVB-039 for the Treatment of Stargardt Disease
BriaCell to Present Bria-OTS+™
BriaCell to Present Bria-OTS+™
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand